Now showing items 1-3 of 3

    • Omalizumab as Third-Line Therapy for Urticaria During Pregnancy 

      Ensina, L. F. [UNIFESP]; Cusato-Ensina, A. P.; Camelo-Nunes, I. C. [UNIFESP]; Sole, D. [UNIFESP] (Esmon Publicidad S A, Dept Allergy, 2017)
    • Omalizumab in chronic spontaneous urticaria: a brazilian real-life experience 

      Ensina, Luis Felipe Chiaverini [UNIFESP]; Rodrigues Valle, Solange Oliveira; Juliani, Ana Paula; Galeane, Michel; dos Santos, Rosaly Vieira; Arruda, Luisa Karla; Lima Melo, Janaina Michelle; de Souza, Patricia Karla [UNIFESP]; Serpa, Faradiba Sarquis; de Andrade, Djanira Martins [UNIFESP]; Franca, Alfeu Tavares; Campos, Regis Albuquerque; Camelo-Nunes, Ines [UNIFESP]; Sole, Dirceu [UNIFESP] (Karger, 2016)
      Background: Current guidelines on chronic spontaneous urticaria (CSU) suggest a treatment based on a 3-step approach that aims at total symptom control, starting with H1 antihistamines. However, a significant number of ...

    • Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic 

      Larenas-Linnemann, Desiree E. S.; Parisi, Claudio A. S.; Ritchie, Carla; Cardona-Villa, Ricardo; Cherrez-Ojeda, Ivan; Cherrez, Annia; Ensina, Luis Felipe [UNIFESP]; Garcia, Elizabeth; Medina, Iris V.; Rodriguez-Gonzalez, Mnica; Sanchez Caraballo, Jorge Mario (Current Medicine Group, 2018)
      Purpose of Review Since omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017 February 2018. Recent Findings Omalizumab ...